Literature DB >> 22017438

The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation.

Marcos W Steinberg1, Timothy C Cheung, Carl F Ware.   

Abstract

The tumor necrosis factor (TNF) receptor superfamily member herpesvirus entry mediator (HVEM) (TNFRSF14) regulates T-cell immune responses by activating both inflammatory and inhibitory signaling pathways. HVEM acts as both a receptor for the canonical TNF-related ligands, LIGHT [lymphotoxin-like, exhibits inducible expression, and competes with herpes simplex virus glycoprotein D for HVEM, a receptor expressed on T lymphocytes] and lymphotoxin-α, and as a ligand for the immunoglobulin superfamily proteins BTLA (B and T lymphocyte attenuator) and CD160, a feature distinguishing HVEM from other immune regulatory molecules. The ability of HVEM to interact with multiple ligands in distinct configurations creates a functionally diverse set of intrinsic and bidirectional signaling pathways that control both inflammatory and inhibitory responses. The HVEM system is integrated into the larger LTβR and TNFR network through extensive shared ligand and receptor usage. Experimental mouse models and human diseases indicate that dysregulation of HVEM network may contribute to autoimmune pathogenesis, making it an attractive target for drug intervention.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017438      PMCID: PMC3381650          DOI: 10.1111/j.1600-065X.2011.01064.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  125 in total

1.  Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.

Authors:  Philippe Le Bouteiller; Aliz Barakonyi; Jérome Giustiniani; Françoise Lenfant; Anne Marie-Cardine; Maryse Aguerre-Girr; Magali Rabot; Ivan Hilgert; Fathia Mami-Chouaib; Julie Tabiasco; Laurence Boumsell; Armand Bensussan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

2.  Cellular localization of nectin-1 and glycoprotein D during herpes simplex virus infection.

Authors:  Claude Krummenacher; Isabelle Baribaud; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Cutting edge: B and T lymphocyte attenuator and programmed death receptor-1 inhibitory receptors are required for termination of acute allergic airway inflammation.

Authors:  Christine Deppong; Twyla I Juehne; Michelle Hurchla; Lindzy D Friend; Dulari D Shah; Christine M Rose; Traci L Bricker; Laurie P Shornick; Erika C Crouch; Theresa L Murphy; Michael J Holtzman; Kenneth M Murphy; Jonathan M Green
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

4.  Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells.

Authors:  Noriko Otsuki; Yousuke Kamimura; Masaaki Hashiguchi; Miyuki Azuma
Journal:  Biochem Biophys Res Commun       Date:  2006-04-21       Impact factor: 3.575

5.  B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs.

Authors:  Jens M Chemnitz; Anthony R Lanfranco; Inbal Braunstein; James L Riley
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

6.  NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors.

Authors:  Zusen Fan; Ping Yu; Yang Wang; Yugang Wang; May Lynne Fu; Wenhua Liu; Yonglian Sun; Yang-Xin Fu
Journal:  Blood       Date:  2005-10-13       Impact factor: 22.113

7.  Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.

Authors:  Yulian Wu; Bing Han; Hongwei Sheng; Min Lin; Paul A Moore; Jun Zhang; Jiangping Wu
Journal:  Int J Cancer       Date:  2003-07-10       Impact factor: 7.396

8.  Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.

Authors:  Victor J Wroblewski; Derrick R Witcher; Gerald W Becker; Kelly A Davis; Shenshen Dou; Radmila Micanovic; Christy M Newton; Timothy W Noblitt; John M Richardson; Ho Yeong Song; John E Hale
Journal:  Biochem Pharmacol       Date:  2003-02-15       Impact factor: 5.858

9.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.

Authors:  Norihiko Watanabe; Maya Gavrieli; John R Sedy; Jianfei Yang; Francesca Fallarino; Susan K Loftin; Michelle A Hurchla; Natalie Zimmerman; Julia Sim; Xingxing Zang; Theresa L Murphy; John H Russell; James P Allison; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2003-06-08       Impact factor: 25.606

10.  Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant.

Authors:  Bengt Johansson-Lindbom; Marcus Svensson; Marc-André Wurbel; Bernard Malissen; Gabriel Márquez; William Agace
Journal:  J Exp Med       Date:  2003-09-08       Impact factor: 14.307

View more
  80 in total

1.  Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT.

Authors:  Tim D Holmes; Erica B Wilson; Emma V I Black; Andrew V Benest; Candida Vaz; Betty Tan; Vivek M Tanavde; Graham P Cook
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

2.  The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion.

Authors:  Ying Zhang; Hildegund C J Ertl
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

Review 3.  The Lymphotoxin Network: orchestrating a type I interferon response to optimize adaptive immunity.

Authors:  Jennifer L Gommerman; Jeffrey L Browning; Carl F Ware
Journal:  Cytokine Growth Factor Rev       Date:  2014-03-12       Impact factor: 7.638

4.  HVEM Imprints Memory Potential on Effector CD8 T Cells Required for Protective Mucosal Immunity.

Authors:  Pritesh Desai; Georges Abboud; Jessica Stanfield; Paul G Thomas; Jianxun Song; Carl F Ware; Michael Croft; Shahram Salek-Ardakani
Journal:  J Immunol       Date:  2017-09-01       Impact factor: 5.422

5.  Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.

Authors:  Michael Boice; Darin Salloum; Frederic Mourcin; Viraj Sanghvi; Rada Amin; Elisa Oricchio; Man Jiang; Anja Mottok; Nicolas Denis-Lagache; Giovanni Ciriello; Wayne Tam; Julie Teruya-Feldstein; Elisa de Stanchina; Wing C Chan; Sami N Malek; Daisuke Ennishi; Renier J Brentjens; Randy D Gascoyne; Michel Cogné; Karin Tarte; Hans-Guido Wendel
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582

Review 6.  T cell co-stimulatory molecules: a co-conspirator in the pathogenesis of eosinophilic esophagitis?

Authors:  Zili Zhang; Thomas J Sferra; Yasemen Eroglu
Journal:  Dig Dis Sci       Date:  2013-03-02       Impact factor: 3.199

Review 7.  Molecular mechanisms of T cell co-stimulation and co-inhibition.

Authors:  Lieping Chen; Dallas B Flies
Journal:  Nat Rev Immunol       Date:  2013-03-08       Impact factor: 53.106

Review 8.  HVEM: An unusual TNF receptor family member important for mucosal innate immune responses to microbes.

Authors:  Jr-Wen Shui; Mitchell Kronenberg
Journal:  Gut Microbes       Date:  2013-01-18

Review 9.  Lymphotoxin network pathways shape the tumor microenvironment.

Authors:  Ryan L Bjordahl; Christian Steidl; Randy D Gascoyne; Carl F Ware
Journal:  Curr Opin Immunol       Date:  2013-01-20       Impact factor: 7.486

Review 10.  Clinical targeting of the TNF and TNFR superfamilies.

Authors:  Michael Croft; Chris A Benedict; Carl F Ware
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.